🏛️ Verified NIH Record • Updated 2026-07-20

Telmisartan in Prostate Cancer (NCT06168487)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Tyler J Curiel

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (15 items) and avoid the listed exclusions (9 items).

Location: Dartmouth Health — Lebanon, New Hampshire

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Participants who fall into one of the following categories will NOT be eligible for this study:
  • Angiotensin l receptor blocker use currently or within the 30 days prior to day 1, cycle 1.
  • Patients with hypertensive urgency or emergency as defined in N Engl J Med. 2019 Nov 7;381(19):1843-1852. doi:10.1056/NEJMep1901117
  • Patients who are incarcerated or homeless
  • Patients who are receiving PC-specific treatment aside from cabazitaxel, docetaxel, olaparib, rucaparib, abiraterone or talazoparib plus enzalutamide or have plans to undergo the same during the study period, except local irradiation therapy to PC lesions.
  • Patients on lithium therapy in any form
  • Patients who received rituximab or amifostine within 30 days prior to first telmisartan dose on this study
  • Patients on ramapril
  • Patients on digoxin who do not consent to monthly digoxin blood level testing

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Dartmouth Health — Lebanon, New Hampshire

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗